– Late-breaking abstract detailing interim data from ongoing clinical trial of OMS906 in treatment-naïve PNH patients selected for June 11, 2023 oral presentation –
Omeros Corporation (NASDAQ:OMER) today announced that data from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company's lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening hemolytic blood disorder, will be shared at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany. Identified as one of the top five late-breaking submissions by the Scientific Program Committee, the abstract was selected for oral presentation.
The presentation, entitled OMS906, A mannan-binding lectin-associated serine protease-3 (MASP-3) Inhibitor, Normalizes Hemoglobin Levels in Treatment-naïve PNH Patients: Interim Data from a Proof-of-Concept Clinical Trial, will be delivered by Jens Panse, MD, Senior Physician and Deputy Director of the Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, and Managing Medical Director of the Center for Integrated Oncology, Aachen, Germany.
Dr. Panse's presentation will be delivered at the late-breaking oral session scheduled for 9:45-11:15 CEST on Sunday, June 11, 2023 and will be available by livestream to registered meeting attendees via the congress platform. The presentation abstract (#LB2714) was embargoed by EHA until 16:00 CEST today but now is freely accessible on EHA's website. Following Dr. Panse's presentation, Omeros will make available on its website the associated slides.
Also at this EHA congress, Morag Griffin, MBChB, FRCPath, Consultant in Haematology of St. James University Teaching Hospital, Leeds, United Kingdom, will present a poster describing findings from a single-ascending dose study evaluating OMS906 safety, pharmacokinetics and pharmacodynamics in healthy subjects. Dr. Griffin's presentation is scheduled for 18:00-19:00 CEST on Friday, June 9, 2023 and will be available for viewing by registered attendees on the online EHA platform throughout the duration of the congress (June 8-11, 2023). The presentation abstract (#P787) is available to everyone on EHA's website.